• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

COPANLISIB Drug Record

  • Summary
  • Interactions
  • Claims
  • COPANLISIB chembl:CHEMBL3218576 ApprovedAntineoplastic

    Alternate Names:

    BAY80-6946
    BAY 80-6946
    COPANLISIB
    BAY-80-6946
    chembl:CHEMBL3218576
    chemidplus:1032568-63-0
    pubchem.compound:24989044
    drugbank:12483

    Drug Info:

    Notes pan-PI3K inhibitor
    Drug Class Kinase Inhibitors
    Pharmaceutical Developer Bayer
    Source Reported Drug Name(s) BAY80-6946
    Drug Class PI3K Inhibitor
    (5 More Sources)

    Publications:

    Patnaik et al., 2016, First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas., Ann. Oncol.
    Liu et al., 2013, BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models., Mol. Cancer Ther.
  • COPANLISIB   PIK3R4

    Interaction Score: 0.45

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenome MyCancerGenomeClinicalTrial

  • COPANLISIB   PIK3R6

    Interaction Score: 0.45

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenome MyCancerGenomeClinicalTrial

  • COPANLISIB   PIK3R1

    Interaction Score: 0.44

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction PI3-kinase class I inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ClearityFoundationBiomarkers MyCancerGenome ChemblInteractions MyCancerGenomeClinicalTrial

  • COPANLISIB   PIK3R5

    Interaction Score: 0.34

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction PI3-kinase class I inhibitor

    PMIDs:
    None found


    Sources:
    MyCancerGenome ChemblInteractions MyCancerGenomeClinicalTrial

  • COPANLISIB   PIK3R3

    Interaction Score: 0.34

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction PI3-kinase class I inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    MyCancerGenome ChemblInteractions MyCancerGenomeClinicalTrial

  • COPANLISIB   PIK3R2

    Interaction Score: 0.3

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction PI3-kinase class I inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    MyCancerGenome ChemblInteractions MyCancerGenomeClinicalTrial

  • COPANLISIB   PIK3C3

    Interaction Score: 0.24

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenome

  • COPANLISIB   PIK3C2G

    Interaction Score: 0.24

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenome

  • COPANLISIB   PIK3C2A

    Interaction Score: 0.24

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenome

  • COPANLISIB   PIK3C2B

    Interaction Score: 0.24

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenome

  • COPANLISIB   PIK3CA

    Interaction Score: 0.23

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction PI3-kinase class I inhibitor
    Indication/Tumor Type colon cancer

    PMIDs:
    27672108 24170767


    Sources:
    ClearityFoundationBiomarkers MyCancerGenome JAX-CKB ChemblInteractions CancerCommons MyCancerGenomeClinicalTrial OncoKB

  • COPANLISIB   PIK3CD

    Interaction Score: 0.23

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction PI3-kinase class I inhibitor

    PMIDs:
    None found


    Sources:
    MyCancerGenome ChemblInteractions MyCancerGenomeClinicalTrial

  • COPANLISIB   PIK3CB

    Interaction Score: 0.21

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction PI3-kinase class I inhibitor

    PMIDs:
    None found


    Sources:
    MyCancerGenome ChemblInteractions MyCancerGenomeClinicalTrial

  • COPANLISIB   PIK3CG

    Interaction Score: 0.12

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction PI3-kinase class I inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    MyCancerGenome ChemblInteractions MyCancerGenomeClinicalTrial

  • COPANLISIB   PTEN

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type endometrial carcinoma
    Response Type sensitive
    Approval Status Phase I

    PMIDs:
    27672108


    Sources:
    ClearityFoundationBiomarkers JAX-CKB

  • COPANLISIB   KRAS

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Copanlisib + Refametinib
    Indication/Tumor Type biliary tract cancer
    Response Type sensitive

    PMIDs:
    24170767


    Sources:
    JAX-CKB

  • COPANLISIB   ERBB2

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type Her2-receptor positive breast cancer
    Response Type sensitive
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    24170767


    Sources:
    JAX-CKB

  • CancerCommons: BAY80-6946

    • Version: 25-July-2013

    Alternate Names:
    66563707 PubChem Drug ID

    Drug Info:
    Drug Class PI3K Inhibitor
    Source Reported Drug Name(s) BAY80-6946
    Pharmaceutical Developer Bayer

    Publications:

  • MyCancerGenome: BAY80-6946

    • Version: 20-Jun-2017

    Alternate Names:

    Drug Info:
    Drug Class Kinase Inhibitors
    Notes pan-PI3K inhibitor

    Publications:

  • JAX-CKB: Copanlisib

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Patnaik et al., 2016, First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas., Ann. Oncol.
    Liu et al., 2013, BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models., Mol. Cancer Ther.

  • ChemblDrugs: chembl:CHEMBL3218576

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationBiomarkers: BAY80-6946

    • Version: 26-July-2013

    Alternate Names:

    Drug Info:

    Publications:

  • MyCancerGenomeClinicalTrial: BAY80-6946

    • Version: 30-February-2014

    Alternate Names:

    Drug Info:

    Publications:

  • OncoKB: Copanlisib

    • Version: 23-July-2020

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL3218576

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • TALC: BAY80-6946

    • Version: 12-May-2016

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21